Expanding sales of Imperial Brands’ next generation products into new markets has more than compensated the company for the effect of the US Food and Drug Administration (FDA)’s marketing denial order (MDO) for its Myblu vaping product.
The company said new markets for vapour, heated tobacco and modern oral products – which it groups together as its next generation product (NGP) segment – brought in more than enough new revenue to offset the loss of Myblu from the US market.
